IMDELLTRA (tarlatamab) for the Treatment of Extensive-Stage Small Cell Lung Cancer, USA
IMDELLTRA™ (tarlatamab) is a first-in-class immunotherapy indicated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have experienced disease progression on or after platinum-based chemotherapy. Developed by Amgen …